# Michael von Bergwelt

Source: https://onco.cc/people/michael-von-bergwelt/  
OnCo record `michael-von-bergwelt` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Michael von Bergwelt is a haematologist who leads LMU's cell therapy and immuno-oncology programme.

## Summary

Michael von Bergwelt is Director of the Department of Medicine III (Hematology and Oncology) at LMU Klinikum München. A haematologist, his specialisms are haematology, cell therapy and immunotherapy toxicity. He leads LMU's cell therapy and immuno-oncology programme, with research on CAR-T cell therapy, T-cell engaging bispecific antibodies and the management of immune-related toxicities. His department combines clinical haematology and oncology with the delivery of these newer immune therapies. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Department of Medicine III (Hematology and Oncology), LMU Munich
- Specialisms: Haematology; Cell therapy; Immunotherapy toxicity

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=von%20Bergwelt-Baildon%20M%5BAuthor%5D%20CAR%20T

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- institutions: [LMU Klinikum München](https://onco.cc/institutions/lmu-munich/)
- terms: [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/)

---
JSON: https://onco.cc/api/v1/entities/michael-von-bergwelt.json